SynDevRx is pioneering the field of metabo-oncology, which focuses on the intersection of metabolic dysfunction and cancer progression. Their lead compound, evexomostat (SDX-7320), is a novel therapy designed to address both cancer and the underlying metabolic hormone imbalances that can exacerbate tumor growth. This drug specifically targets dysregulated metabolic hormones such as insulin, leptin, and adiponectin, which are often associated with obesity and diabetes. By improving the tumor microenvironment and correcting systemic metabolic dysfunction, evexomostat aims to enhance the effectiveness of standard cancer treatments and improve patient outcomes.

The company is actively conducting clinical trials to evaluate the safety and efficacy of evexomostat in various cancer types, particularly in patients with metabolic disorders. Their approach combines evexomostat with existing therapies to create a multi-modal treatment strategy that addresses both the cancer and the metabolic issues that may hinder treatment success. SynDevRx's commitment to this underexplored area of drug development positions them as a leader in metabo-oncology, with the potential to significantly impact the lives of cancer patients who also suffer from metabolic dysfunction.

United States

SynDevRx is the first company developing treatments for cancer patients with baseline (or acquired) metabolic dysfunction with the only drug in clinical development that targets the underlying metabolic defect in cancer cells. The company's therapies focus on treating tumors sensitive to systemic, dysregulated metabolic hormones.

SynDevRx

Company Details